歐林生物股票討論區

Chengdu Olymvax Biopharmaceuticals' decent financial indicators and higher than average net income growth suggest potential for long-term stock price increase. The company's strategy of reinvesting all of its profits and the expected continuation of earnings expansion are seen as positive attributes.

Chengdu Olymvax Biopharmaceuticals' high P/S ratio may not be justified due to less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable. Also, there are 3 warning signs to consider.

Despite weak revenue forecasts, the company's P/S ratio remains high, which could lead to significant investment risk if the high P/S ratio drops.

Chengdu Olymvax Biopharmaceuticals' ROE may be below industry average, but its steady net income growth could imply efficient management. With an expected earnings acceleration and all profits reinvested, the investment outlook seems positive.